http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105560217-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-575 |
| filingDate | 2016-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105560217-B |
| titleOfInvention | Application of Honokiol in Acute Myeloid Leukemia |
| abstract | The invention discloses the application of honokiol in acute myeloid leukemia. Honokiol is used to treat leukemia and prepare leukemia drugs. Honokiol specifically targets and degrades AML1-ETO protein through the UBCH8 ubiquitination pathway, which can be used for the application of M2 acute myeloid leukemia. In the present invention, Honokiol is used for rapid and specific targeted degradation of endogenous and exogenous expressed AML1-ETO fusion protein, and its function and ubiquitination mechanism are proposed, which have been proved in molecular biology and zebrafish model application, Honokiol can degrade AML1‑ETO protein, thereby achieving anti-leukemia therapeutic effect. |
| priorityDate | 2016-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 149.